# A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa

> **NCT05459532** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Witwatersrand, South Africa** · enrollment: 59 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Molnupiravir 200 mg

## Key facts

- **NCT ID:** NCT05459532
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-09-30
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05459532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05459532, "A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05459532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*